Patents Assigned to Xenon Genetics, Inc.
  • Publication number: 20090060900
    Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.
    Type: Application
    Filed: June 11, 2007
    Publication date: March 5, 2009
    Applicant: Xenon Genetics Inc.
    Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka
  • Patent number: 7256028
    Abstract: Drug screening assays useful in the discovery of pharmaceutically active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy are taught. In particular, the control region of delta-5-desaturase gene is taught as a target for the drug screening methods, which serve to identify nucleotides, proteins, compounds and/or other pharmacological agents, which modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes. Cell-based and cell lysate assays are taught for detecting components that interact with the desaturase enzymes and modify fatty acid profiles. In addition, cell-based and cell lysate assays are used to identify functional and regulatory elements controlling expression of the desaturase genes as well as to screen for components that modulate the transcriptional activity of the desaturase genes. Also taught is the gene for rat delta-5-desaturase.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: August 14, 2007
    Assignee: Xenon Genetics Inc.
    Inventors: Michael David Winther, Leah Christine Knickle, Martin Haardt, Stephen John Allen, Andre Ponton, Roberto Justo De Antueno, D. Kenneth Jenkins, Solomon O. Nwaka
  • Patent number: 7166584
    Abstract: Methods and compounds are disclosed for lowering serum LDL levels or serum cholesterol levels, or for reducing the transport of cholesterol from the gut to the blood or the lymph, based on the observation that a gene known as ABC1 is necessary in order for cholesterol to be transported from the intestinal lumen into the bloodstream. A mutant chicken phenotype, known as the WHAM chicken, characterized by low levels of serum LDL and reduced transport of cholesterol, facilitated the discovery of this function of the ABC1 gene. Techniques which act to inhibit ABC1 activity in the cells of the intestinal wall will result in lower serum cholesterol.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: January 23, 2007
    Assignees: Wisconsin Alumni Research Foundation, Xenon Genetics, Inc.
    Inventors: Alan D. Attie, Mark Cook, Mark P. Gray-Keller, Michael R. Hayden, Simon Pimstone, Angela R. Brooks-Wilson
  • Patent number: 6759208
    Abstract: High throughput screening assays for the identification of potential therapeutic agents able to modulate the activity of enzymes of fatty acid biosynthesis, especially desaturases and/or elongases, are disclosed along with therapeutic uses of the agents identified by such assays for the prevention and/or treatment of diseases related to fatty acid metabolism. Substrates useful in such assays are also described.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: July 6, 2004
    Assignee: Xenon Genetics Inc.
    Inventors: Michael D. Winther, Mark P. Gray-Keller
  • Patent number: 6617122
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 9, 2003
    Assignee: Xenon Genetics, Inc.
    Inventors: Michael R. Hayden, Angela R. Brooks-Wiison, Simon N. Pimstone